Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

Autor: C Hernández-Fernández, G Carretero, R Rivera, C Ferrándiz, E Daudén, P Cueva, I Belinchón, F Gómez-García, E Herrera-Acosta, D Ruiz-Genao, M Ferrán, M Alsina, O Baniandrés-Rodríguez, J Sánchez-Carazo, R Botella-Estrada, A Sahuquillo-Torralba, L Rodríguez, J Vilar-Alejo, C García-Donoso, J Carrascosa, M Llamas-Velasco, E Herrera-Ceballos, J López-Estebaranz, C Pujol-Marco, M Descalzo, I Garcia-Doval, a Group
Přispěvatelé: UAM. Departamento de Medicina
Rok vydání: 2021
Předmět:
Zdroj: ACTA DERMATO-VENEREOLOGICA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Acta Dermato-Venereologica, Vol 101, Iss 1, p adv00354 (2021)
Acta Dermato-Venereologica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Biblos-e Archivo. Repositorio Institucional de la UAM
ISSN: 0001-5555
1651-2057
Popis: "Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM".
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be pre-scribed biologics. There were no differences between men and women in effectiveness of therapy, measur-ed in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios) and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, Janssen and Almirall).
Databáze: OpenAIRE